IL135126A0 - Perforated microparticles and methods of use and preparation thereof - Google Patents

Perforated microparticles and methods of use and preparation thereof

Info

Publication number
IL135126A0
IL135126A0 IL13512698A IL13512698A IL135126A0 IL 135126 A0 IL135126 A0 IL 135126A0 IL 13512698 A IL13512698 A IL 13512698A IL 13512698 A IL13512698 A IL 13512698A IL 135126 A0 IL135126 A0 IL 135126A0
Authority
IL
Israel
Prior art keywords
dispersions
patient
preparation
methods
suspension medium
Prior art date
Application number
IL13512698A
Other languages
English (en)
Original Assignee
Inhale Therapeutic Syst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL135126(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inhale Therapeutic Syst filed Critical Inhale Therapeutic Syst
Publication of IL135126A0 publication Critical patent/IL135126A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
IL13512698A 1997-09-29 1998-09-29 Perforated microparticles and methods of use and preparation thereof IL135126A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6033797P 1997-09-29 1997-09-29
US10693298A 1998-06-29 1998-06-29
US13384898A 1998-08-14 1998-08-14
PCT/US1998/020602 WO1999016419A1 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use

Publications (1)

Publication Number Publication Date
IL135126A0 true IL135126A0 (en) 2001-05-20

Family

ID=27369827

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13512698A IL135126A0 (en) 1997-09-29 1998-09-29 Perforated microparticles and methods of use and preparation thereof
IL135126A IL135126A (en) 1997-09-29 2000-03-16 Perforated microparticles and methods for using and preparing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL135126A IL135126A (en) 1997-09-29 2000-03-16 Perforated microparticles and methods for using and preparing them

Country Status (28)

Country Link
EP (4) EP1019021B2 (cs)
JP (9) JP4526702B2 (cs)
KR (4) KR100575070B1 (cs)
CN (1) CN1169520C (cs)
AT (3) ATE239447T1 (cs)
AU (4) AU757337C (cs)
BG (1) BG64816B1 (cs)
BR (1) BR9812693A (cs)
CA (4) CA2304973C (cs)
CZ (1) CZ300758B6 (cs)
DE (2) DE69814428T2 (cs)
DK (2) DK1019022T4 (cs)
EA (2) EA003665B1 (cs)
EE (1) EE04628B1 (cs)
ES (3) ES2195408T5 (cs)
HK (1) HK1031680A1 (cs)
HR (1) HRP20000175B1 (cs)
IL (2) IL135126A0 (cs)
IS (1) IS2154B (cs)
ME (1) MEP4108A (cs)
NO (1) NO340149B1 (cs)
NZ (1) NZ503464A (cs)
PL (1) PL195212B1 (cs)
PT (1) PT1019022E (cs)
RS (1) RS50182B (cs)
SK (1) SK285068B6 (cs)
TR (1) TR200000819T2 (cs)
WO (3) WO1999016422A1 (cs)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
JP4526702B2 (ja) * 1997-09-29 2010-08-18 ネクター セラピューティックス 安定化生物活性処方物およびその使用方法
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
GB9727102D0 (en) * 1997-12-22 1998-02-25 Andaris Ltd Microparticles and their therapeutic use
WO2000000215A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
KR100796220B1 (ko) * 1998-06-29 2008-01-21 넥타르 테라퓨틱스 미립자 전달 시스템 및 사용 방법
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6223455B1 (en) † 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
ATE312601T1 (de) * 1999-05-27 2005-12-15 Acusphere Inc Poröse arzneistoffmatrizen und deren herstellungsverfahren
AU782916B2 (en) 1999-06-09 2005-09-08 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
WO2001045731A1 (en) 1999-12-21 2001-06-28 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
JP2003522304A (ja) 2000-02-08 2003-07-22 スリーエム イノベイティブ プロパティズ カンパニー インク定着材料およびインク定着方法
JP2003522058A (ja) 2000-02-08 2003-07-22 スリーエム イノベイティブ プロパティズ カンパニー 改善された常温画像転写媒体
GB0003935D0 (en) * 2000-02-08 2000-04-12 King S College London Formulation for dry powder inhaler
DK1280520T4 (en) * 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
WO2001087277A2 (en) * 2000-05-15 2001-11-22 Vectura Limited Method of manufacturing particles
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7141236B2 (en) 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
DE10064219B9 (de) * 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US20030072717A1 (en) 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
JP2004528339A (ja) * 2001-04-26 2004-09-16 ネクター セラピューティクス 気道に対して又は気道を介して高分子を送達するための新規方法及び組成物
US7905230B2 (en) 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
EP1389137B1 (en) * 2001-05-21 2006-07-19 InJet Digital Aerosols Limited Compositions for protein delivery via the pulmonary route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
CA2641760A1 (en) 2001-05-24 2002-11-28 Alexza Pharmaceuticals, Inc. Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2002094242A1 (en) 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of rizatriptan or zolmitriptan through an inhalation route
WO2003000326A1 (en) 2001-06-20 2003-01-03 Nektar Therapeutics Powder aerosolization apparatus and method
JP2005507881A (ja) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
EP1446104B2 (en) 2001-11-01 2011-08-03 Novartis AG Spray drying methods
AU2002363947A1 (en) 2001-11-21 2003-07-24 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1458630A1 (en) 2001-12-21 2004-09-22 Nektar Therapeutics Capsule package with moisture barrier
KR20040093155A (ko) * 2002-03-18 2004-11-04 야마노우치세이야쿠 가부시키가이샤 흡입용 분말 의약조성물 및 이의 제조방법
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US6941980B2 (en) 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
PA8578501A1 (es) 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
JP2006503865A (ja) * 2002-09-30 2006-02-02 アキュスフィア， インコーポレイテッド 吸入のための徐放性の多孔性微粒子
US7516741B2 (en) 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
AU2003287132B2 (en) * 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7669596B2 (en) 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
ES2589578T5 (es) * 2002-12-31 2019-07-23 Novartis Ag Formulación farmacéutica con un agente activo insoluble para administración pulmonar
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
WO2004075913A1 (ja) * 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
DK1615689T3 (da) 2003-04-09 2016-03-14 Novartis Ag Apparatur til dannelse af en aerosol og omfattende en opretningsføring til punktering af en kapsel
PT1610850E (pt) 2003-04-09 2012-06-15 Novartis Ag Dispositivo para gerar um aerossol com protecção da entrada de ar
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
MXPA05012821A (es) 2003-05-28 2006-02-13 Nektar Therapeutics Formulacion farmaceutica que comprende un agente activo insoluble en agua.
BRPI0414907A (pt) * 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US7621299B2 (en) 2003-10-03 2009-11-24 Cabot Corporation Method and apparatus for filling a vessel with particulate matter
CA2543296A1 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
US7192919B2 (en) 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
KR20070009639A (ko) * 2004-04-13 2007-01-18 캠브리지 바이오스테빌리티 리미티드 부유 유리 입자를 함유한 액체
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
BRPI0512326A (pt) 2004-06-21 2008-02-26 Nektar Therapeutics composições compreendendo anfotericina b, métodos e sistemas
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
EP1785145A4 (en) 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
WO2006015942A1 (en) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006015943A2 (en) 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EA200702049A1 (ru) * 2005-03-23 2008-02-28 Элан Фарма Интернэшнл Лтд. Композиции наночастиц кортикостероидов с антигистаминами
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
WO2006124446A2 (en) * 2005-05-12 2006-11-23 Nektar Therapeutics Sustained release microparticles for pulmonary delivery
KR101348594B1 (ko) 2005-05-18 2014-01-07 노바르티스 아게 기관지 치료를 위한 밸브, 장치 및 방법
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
EP2452694B1 (en) 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
JP5113328B2 (ja) * 2005-11-07 2013-01-09 田辺三菱製薬株式会社 エマルション並びにそれを用いた目的物質粒子の製造方法及び医薬品
ES2390286T3 (es) 2005-12-16 2012-11-08 Nektar Therapeutics Conjugados poliméricos de GLP-1
SI2548577T1 (sl) 2005-12-29 2017-05-31 Janssen Biotech, Inc. Človeška protitelesa proti il-23, sestavki, postopki in uporabe
WO2007086039A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of producing porous microparticles
CA2651855C (en) 2006-05-30 2011-08-02 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
WO2008078730A1 (ja) * 2006-12-26 2008-07-03 Translational Research, Ltd. 経鼻投与用製剤
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2009023803A2 (en) * 2007-08-15 2009-02-19 Abbott Respiratory Llc Modulated release formulation for the delivery of one or more medicaments
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2009120619A2 (en) * 2008-03-24 2009-10-01 Novartis Ag Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
PL220269B1 (pl) 2008-04-21 2015-09-30 Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
EP2285345A1 (en) 2008-05-15 2011-02-23 Novartis AG Pulmonary delivery of a fluoroquinolone
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EA028304B1 (ru) 2008-10-31 2017-11-30 Сентокор Орто Байотек Инк. Способы конструирования библиотеки белкового каркаса на основе домена фибронектина типа iii (fn3)
BRPI0916047A2 (pt) * 2008-11-04 2015-11-10 Cipla Ltd composição farmacêutica em aerossol, uso de uma composição farmacêutica em aerossol, método para tratamento de sintomas crônicos ou agudos severos, moderados ou leves, ou para tratamento profilático de um distúrbio respiratório, dispensador farmacêutico em aerossol, processo para fabricação de um dispensador farmacêutico em aerossol e processo para fabricação de um complexo de um agente ativo e um adjuvante
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
EP2221048A1 (en) 2009-02-18 2010-08-25 Siegfried Generics International AG Pharmaceutical composition for inhalation
JP2012520890A (ja) 2009-03-18 2012-09-10 インカーダ セラピューティクス， インコーポレイテッド 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
CA2754691C (en) 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2010131486A1 (en) 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
KR20100123240A (ko) * 2009-05-15 2010-11-24 포항공과대학교 산학협력단 호흡기 염증성 질환의 치료 또는 예방을 위한 호흡기내 투여용 약학 제제 및 상기 질환의 치료 또는 예방 방법
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CN105193773B (zh) * 2009-05-29 2018-12-11 珍珠治疗公司 活性剂的呼吸递送
WO2011013003A2 (en) 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
EP2462246B1 (en) 2009-09-28 2017-09-06 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011069197A1 (en) * 2009-12-08 2011-06-16 The University Of Sydney Inhalable formulations
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
JP5877204B2 (ja) 2010-09-29 2016-03-02 パルマトリックス，インコーポレイテッド 吸入用の一価金属カチオン乾燥粉末
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
CN103228266B (zh) * 2010-10-29 2017-11-14 健康科学西部大学 三元混合物制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012116362A2 (en) * 2011-02-25 2012-08-30 The Johns Hopkins University Chalcone derivatives as nrf2 activators
GB201108039D0 (en) * 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
KR20140032404A (ko) * 2011-05-17 2014-03-14 펄 테라퓨틱스 인코포레이티드 ２ 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 ＆ 시스템
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EP2601941A1 (en) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
CA3111941A1 (en) 2012-10-25 2014-05-01 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
KR101543507B1 (ko) * 2013-05-15 2015-08-11 씨제이헬스케어 주식회사 연속 공정의 미립구의 제조 방법 및 이로부터 제조된 미립구
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2913235C (en) * 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
CN110305095A (zh) 2013-10-22 2019-10-08 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
EP3725311A1 (en) 2014-02-10 2020-10-21 Respivant Sciences GmbH Methods for the treatment of lung diseases with mast cell stabilizers
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
CA2991760A1 (en) 2014-07-31 2016-02-04 Otitopic Inc. Dry powder formulations for inhalation
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
JP6395216B2 (ja) * 2014-11-13 2018-09-26 国立大学法人大阪大学 液体に含まれる超微細バブルの測定方法及びその測定装置
US10668015B2 (en) 2015-01-20 2020-06-02 Incarda Therapeutics, Inc. Unit aerosol doses for anticoagulation
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
US10864190B2 (en) 2015-04-22 2020-12-15 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3701940A1 (en) 2015-12-04 2020-09-02 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
HRP20211466T1 (hr) 2015-12-09 2021-12-24 Medizinische Universität Wien Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka
EP3402788A1 (en) 2016-01-15 2018-11-21 Universität Hamburg Flavonoide-type compounds bearing an o-rhamnosyl residue
IL260335B2 (en) 2016-02-01 2023-10-01 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
WO2017140728A1 (en) 2016-02-15 2017-08-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody
WO2017178820A1 (en) 2016-04-15 2017-10-19 Oxford University Innovation Limited Adenosine receptor modulators for the treatment of circadian rhythm disorders
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN109715670A (zh) 2016-07-15 2019-05-03 波赛达治疗公司 对muc1特异性的嵌合抗原受体(car)及其使用方法
WO2018014038A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors and methods for use
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYNE COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONARY FIBROSIS
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017328905C1 (en) 2016-09-19 2020-08-06 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
ES2841649T5 (es) 2016-09-19 2024-04-24 Mexichem Fluor Sa De Cv Composición farmacéutica
MX2019003098A (es) 2016-09-19 2019-08-01 Mexichem Fluor Sa De Cv Composicion farmaceutica.
AU2017328910B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
KR20240046648A (ko) 2016-09-30 2024-04-09 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
WO2018087401A2 (en) 2016-11-14 2018-05-17 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
CA3044244A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il23 specific antibody
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
KR20200003199A (ko) 2017-05-10 2020-01-08 인카다 테라퓨틱스, 인크. 폐 투여에 의해 심장 병태를 치료하기 위한 단위 용량, 에어로졸, 키트 및 방법
AU2018271873B2 (en) 2017-05-22 2023-11-02 Insmed Incorporated Glycopeptide derivative compounds and uses thereof
EP3654946A4 (en) 2017-07-20 2021-04-21 AZTherapies, Inc. POWDER FORMULATIONS OF CROMOLYN SODIUM AND IBUPROFEN
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
WO2019110139A1 (en) 2017-12-05 2019-06-13 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
CA3086187A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
EP3762015A4 (en) 2018-03-05 2022-04-27 Janssen Biotech, Inc. METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
AU2019230192A1 (en) 2018-03-07 2020-10-08 Poseida Therapeutics, Inc. CARTyrin compositions and methods for use
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
EA202092326A1 (ru) 2018-04-06 2021-03-19 Цилентин Аг Производные буметанида для лечения гипергидроза
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
US20190345245A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
PT3883606T (pt) 2018-09-24 2023-10-18 Janssen Biotech Inc Método seguro e eficaz de tratamento da colite ulcerosa com anticorpo anti il12/il23
CA3120237A1 (en) 2018-11-20 2020-05-28 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il-23 specific antibody
AU2019407650B2 (en) 2018-12-17 2022-10-27 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
MA54562A (fr) 2018-12-18 2021-10-27 Janssen Biotech Inc Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23
WO2020142707A1 (en) 2019-01-03 2020-07-09 Aqua Yield Operations LLC Pamam dendrimers for fertilizer delivery
CA3133395A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
CA3134079A1 (en) 2019-03-18 2020-09-24 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
US11932585B2 (en) * 2019-04-12 2024-03-19 Aqua Yield Operations LLC Blended nanoparticle fertilizer delivery
CN110051868A (zh) * 2019-04-15 2019-07-26 宝盈联华(厦门)生物科技有限公司 一种带有硅碳岩、礌石粉的橱柜灭菌器
JP7404671B2 (ja) * 2019-06-25 2023-12-26 株式会社リコー 多孔質微粒子及びその製造方法、並びに医薬組成物
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021064141A1 (en) 2019-10-02 2021-04-08 Tolremo Therapeutics Ag Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
MX2022003617A (es) 2019-10-02 2022-05-30 Tolremo Therapeutics Ag Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.
WO2021074418A1 (en) 2019-10-16 2021-04-22 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
AU2020366135A1 (en) 2019-10-16 2022-06-02 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
BR112022020650A2 (pt) 2020-04-14 2023-01-31 Poseida Therapeutics Inc Composições e métodos para uso no tratamento de câncer
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
US20230226057A1 (en) 2020-06-25 2023-07-20 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
EP3939578A1 (en) 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
CN111700883B (zh) * 2020-07-23 2021-04-06 深圳大佛药业股份有限公司 一种硫酸沙丁胺醇缓释型吸入制剂及其生产工艺
EP3964497A1 (en) 2020-09-04 2022-03-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
WO2022049382A1 (en) 2020-09-04 2022-03-10 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
CA3194868A1 (en) 2020-10-16 2022-04-21 Georg Winter Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
CN112495316B (zh) * 2020-10-20 2021-11-19 大连理工大学 一种基于亚稳态乳液制备微纳米凝胶微球的方法
WO2022122012A1 (zh) * 2020-12-11 2022-06-16 江苏恒瑞医药股份有限公司 用于肺部递送的药物组合物
WO2022190033A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
CN117355512A (zh) 2021-04-07 2024-01-05 托雷莫治疗股份公司 杂环衍生物、药物组合物及其在治疗或改善癌症中的用途
EP4367138A1 (en) 2021-07-09 2024-05-15 Janssen Biotech, Inc. Manufacturing methods for producing anti-il12/il23 antibody compositions
EP4423126A1 (en) 2021-10-29 2024-09-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
KR20240107176A (ko) 2021-11-15 2024-07-08 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
CA3239216A1 (en) 2021-11-23 2023-06-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023203174A1 (en) 2022-04-20 2023-10-26 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
WO2023223265A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
CN115144310B (zh) * 2022-07-01 2024-07-19 重庆交通大学 一种旋桨式絮凝沉降试验装置及方法
US20240199734A1 (en) 2022-11-22 2024-06-20 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1410588A (en) † 1971-08-10 1975-10-22 Fisons Ltd Composition
JPS5134879A (en) * 1974-09-19 1976-03-24 Eisai Co Ltd Bishochukuryushinoseizoho
US4147766A (en) † 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
DE3268533D1 (en) † 1981-07-24 1986-02-27 Fisons Plc Inhalation drugs, methods for their production and pharmaceutical formulations containing them
ATE93384T1 (de) * 1983-11-14 1993-09-15 Univ Kentucky Res Found Poroese mikrokugeln zur arzneistoffabgabe sowie verfahren zu deren herstellung.
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
GB8502892D0 (en) * 1985-02-05 1985-03-06 Sterwin Ag Aerosol composition
ATE78158T1 (de) * 1985-05-22 1992-08-15 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4950477A (en) † 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
AU620253B2 (en) * 1989-05-01 1992-02-13 Alkermes Controlled Therapeutics, Inc. Process for producing small particles of biologically active molecules
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
JPH05507090A (ja) * 1990-05-08 1993-10-14 リポサーム　テクノロジー　インコーポレイテッド 直接噴霧乾燥された薬剤／脂質粉末組成物
US5126123A (en) † 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) † 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5304125A (en) † 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
DE69124357T2 (de) * 1991-01-15 1997-07-10 Hemosphere Inc Protein Nanomatrizen und Verfahren zur Herstellung
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5182097A (en) † 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
NZ241954A (en) † 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
JPH05500229A (ja) * 1991-04-12 1993-01-21 東レ株式会社 固体ポリペプチド微粒子のエアロゾル製剤とその製造方法
US5474759A (en) * 1991-06-10 1995-12-12 Schering Corporation Non-chlorofluorocarbon aerosol formulations
DE69218455T2 (de) * 1991-12-18 1997-10-23 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Aerosolzusammensetzungen für arzneimittelsuspensionen
US5376359A (en) † 1992-07-07 1994-12-27 Glaxo, Inc. Method of stabilizing aerosol formulations
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5354934A (en) † 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
ES2231775T5 (es) * 1993-07-30 2011-02-02 Imcor Pharmaceutical Co. Composición de microburbujas estabilizadas para ecografía.
US5798091A (en) † 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
JPH10506406A (ja) * 1994-09-29 1998-06-23 アンダリス、リミテッド 治療用ビヒクルとしての噴霧乾燥させた微細粒子
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6932962B1 (en) * 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US6136346A (en) * 1995-04-14 2000-10-24 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
US5654007A (en) * 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
ATE265863T1 (de) † 1995-06-07 2004-05-15 Imarx Pharmaceutical Corp Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
GB9606677D0 (en) * 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
JP3884484B2 (ja) † 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー 吸入用粒子の調製
JP4526702B2 (ja) * 1997-09-29 2010-08-18 ネクター セラピューティックス 安定化生物活性処方物およびその使用方法

Also Published As

Publication number Publication date
CA2304820A1 (en) 1999-04-08
CZ20001115A3 (cs) 2000-09-13
AU757337C (en) 2005-11-03
SK285068B6 (sk) 2006-05-04
KR100589926B1 (ko) 2006-06-15
YU18300A (sh) 2003-02-28
JP4526702B2 (ja) 2010-08-18
DE69813853T2 (de) 2004-01-29
JP2003525842A (ja) 2003-09-02
MEP4108A (xx) 2010-02-10
JP2011116788A (ja) 2011-06-16
KR20010030787A (ko) 2001-04-16
CA2304973A1 (en) 1999-04-08
JP2013199497A (ja) 2013-10-03
JP5372306B2 (ja) 2013-12-18
ES2205560T5 (es) 2013-04-16
JP5739197B2 (ja) 2015-06-24
PL339732A1 (en) 2001-01-02
EP1019020A1 (en) 2000-07-19
ES2195415T3 (es) 2003-12-01
AU1185799A (en) 1999-04-23
KR100575070B1 (ko) 2006-05-03
AU750567B2 (en) 2002-07-25
HK1031680A1 (en) 2001-06-22
AU9677098A (en) 1999-04-23
EA003665B1 (ru) 2003-08-28
ES2195408T3 (es) 2003-12-01
EP1019021B1 (en) 2003-09-03
DE69814428D1 (de) 2003-06-12
DE69813853D1 (de) 2003-05-28
DK1019021T4 (da) 2013-01-07
JP6078498B2 (ja) 2017-02-08
AU756693B2 (en) 2003-01-23
CA2304819A1 (en) 1999-04-08
NO340149B1 (no) 2017-03-13
EP1019021B2 (en) 2012-12-26
PT1019022E (pt) 2003-08-29
JP6100114B2 (ja) 2017-03-22
IS2154B (is) 2006-10-13
CA2304975A1 (en) 1999-04-08
EP1019021A1 (en) 2000-07-19
EP1019022B2 (en) 2010-07-28
CN1169520C (zh) 2004-10-06
CZ300758B6 (cs) 2009-08-05
TR200000819T2 (tr) 2001-06-21
DK1019022T3 (da) 2003-07-28
ATE239447T1 (de) 2003-05-15
CN1272058A (zh) 2000-11-01
NO20001618L (no) 2000-05-19
JP2013216688A (ja) 2013-10-24
SK4492000A3 (en) 2000-09-12
PL195212B1 (pl) 2007-08-31
WO1999016419A9 (en) 1999-08-19
ATE248583T1 (de) 2003-09-15
IS5415A (is) 2000-03-24
AU1064499A (en) 1999-04-23
EP1019022B1 (en) 2003-04-23
IL135126A (en) 2006-04-10
JP2001517691A (ja) 2001-10-09
JP2014169335A (ja) 2014-09-18
AU757153B2 (en) 2003-02-06
BG104253A (en) 2000-11-30
EA002562B1 (ru) 2002-06-27
KR100572171B1 (ko) 2006-04-19
EA200000375A1 (ru) 2000-12-25
KR100599634B1 (ko) 2006-07-12
EP1019023B1 (en) 2003-05-07
NO20001618D0 (no) 2000-03-28
DE69814428T2 (de) 2004-05-13
KR20010030788A (ko) 2001-04-16
ATE238035T1 (de) 2003-05-15
ES2205560T3 (es) 2004-05-01
DK1019021T3 (da) 2003-11-10
WO1999016421A1 (en) 1999-04-08
AU9677298A (en) 1999-04-23
RS50182B (sr) 2009-05-06
AU757337B2 (en) 2003-02-20
CA2304819C (en) 2008-04-08
DK1019022T4 (da) 2010-11-08
CA2304975C (en) 2009-06-16
EE200000194A (et) 2001-04-16
HRP20000175B1 (en) 2004-06-30
BR9812693A (pt) 2000-08-22
NZ503464A (en) 2002-05-31
BG64816B1 (bg) 2006-05-31
WO1999016419A1 (en) 1999-04-08
CA2304820C (en) 2009-06-23
EP1019022A1 (en) 2000-07-19
JP2003525841A (ja) 2003-09-02
WO1999016422A1 (en) 1999-04-08
EP1019023A1 (en) 2000-07-19
DE69813853T3 (de) 2011-05-12
KR20010030801A (ko) 2001-04-16
EA200200036A1 (ru) 2002-04-25
CA2304973C (en) 2009-11-17
EE04628B1 (et) 2006-06-15
KR20010030810A (ko) 2001-04-16
HRP20000175A2 (en) 2001-06-30
ES2195408T5 (es) 2010-11-25
JP2010047615A (ja) 2010-03-04
JP2001517692A (ja) 2001-10-09

Similar Documents

Publication Publication Date Title
IL135126A0 (en) Perforated microparticles and methods of use and preparation thereof
GB9606677D0 (en) Process and device
ATE164060T1 (de) Inhalationspulver und verfahren zu ihrer herstellung
WO2002024158A3 (en) Pulmonary delivery in treating disorders of the central nervous system
EP3494995A3 (en) Formoterol superfine formulation
WO2001064182A3 (en) Improvements in or relating to the delivery of oral drugs
KR930701992A (ko) 환자의 폐에 잔존하는 점액 분비물의 제거 방법
AU3598299A (en) Improved compositions for inhalation
CZ287114B6 (en) Therapeutic preparation in the form of aerosol and use of gas mixture

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed